Pharmacology 14 Drugs Review Flashcards
Acetaminophen Classification/Indication
Analgesic/Antipyretic
Analgesia, Fever
Acetaminophen Dosing
IR: 325-650mg PO/PR q4h
ER: 1000mg PO Q6-8h
Acetaminophen MOA
Acts on the hypothalamus to produce antipyresis.
Peripherally works to block pain impulse generation
May inhibit prostaglandin synthesis in CNS
Acetaminophen ADE’s
Angioedema
Disorientation/dizziness
Pruritic, maculopapular rash
Acetaminophen Elimination
Hepatic Metabolism
Excreted in urine
Acetaminophen Clinical Pearls
Pregnancy Cat B
Avoid Doses >3250 mg daily
Amlodipine Classification/ Indication
Antihypertensive
Hypertension, Coronary Artery Disease, Angina
Amlodipine Dosing
5mg PO D; may increase q7-14d. NTE 10mg PO D
Amlodipine MOA
CCB; inhibits cardiac and vascular smooth muscle contraction. Leads to dilation of main coronary & systemic arteries
Amlodipine ADE
Edema/Pulmonary Edema
HA
Fatigue
Amlodipine Elimination
Hepatic metabolism
Excreted in urine
Amlodipine Clinical Pearls
Comes in combo w/ Benazepril, atorvastatin, olmesartan, Telmisartan, Valsartan.
Use w/caution in CHF
Titrate slowly in those w/severe hepatic impairment due to extensive liver metabolism
Aspirin Classification/Indication
NSAID, Antiplatelet
Pain, Fever
Acute Coronary Syndrome
Aspirin Dosing
P/F: 325-650mg PO/PR q4-6h PRN
ACS: 160-325 mg PO; chew non enteric coated tablet upon presentation. Maintanance dosing 81-325 mg D
Aspirin MOA
Inhibits synthesis of prostaglandins by blocking COX
Inhibits platelet aggregation
Has antipyretic/analgesic activity
Aspirin ADE
Angiodema, uticaria, rash
Bronchospasm
CNS alteration
Aspirin Elimination
Hepatic metabolism
Excreted mostly in urine, some in sweat, saliva, feces
Aspirin Clinical Pearls
Contraindicated: Bleeding, GI Ulcers, hemophelia, hemorrhoids, lactating mothers, nasal polyps.
Associated with asthma, sarcoidosis, throbocytopenia, UC
Avoid in pediatrics due to increased incidence of Reyes syndrome
May worsen CHF in pts due to increased NA/H2O retention due to prostaglandin inhibition
Atorvastatin Classification/Indication
Hypolipemic
Hyperlipidemia
Atorvastatin Dosing
10-80 mg PO D
Atorvastatin MOA
Inhibits rate limiting step in cholesterol biosynthesis by inhibiting HMG-CoA reductase
Atorvastatin ADE
N/D/dyspepsia
Nasopharyngitis
Arthralgia
Atorvastatin Elimination
Hepatic metabolism
Excreted mainly in bile
Atorvastatin Clinical Pearls
May cause elevations in LFTs
Risk of myopathy increased by coadmin of HIV protease inhibitors or azole antifungals
Glyburide (Micronase) Classification/Indication
Antidiabetic
Diabetes
Glyburide Dosing
1.25-20mg PO D. MDD 20mg D
Glyburide MOA
Sulfonylurea enhances insulin secretion from pancreatic beta cells.
Increase peripheral utilization of glucose
Suppresses hepatic gluconeogenesis, and possibly increase sensitivity and/or # of peripheral insulin receptors
Glyburide ADE
Noctural enuresis
Hypoglycemia, Nausea, myalgia, skin rash, heartburn
Disulfiram reaction, hemolytic anemia
Glyburide Elimination
Renal elimination 50%
Glyburide Clinical Pearls
May have symptoms of hypoglycemia masked by beta blockers (except sweating)
Monitor blood glucose 2-4x D
Alcohol may cause disulfiram reaction
Often add-on therapy w/metformin if A1C goals are not met
Hydrochlorothiazide (Hydrodiuril) Classification/Indication
Diuretic
Hypertension, edema
HCTZ Dosing
Edema 25-100mg PO D in single or divided doses
HTN: Initial 12.5-25mg PO D
HCTZ MOA
Thizides increase NA/CL excretion by interfering with their reabosorption in the cortical diluting segment of the nephron
HCTZ ADE
Hypotension, dizziness, HA
Constipation, nausea, impotence
Hyper-calcemia/glycemia/uricemia
Hypo-kalemia/magnesemia/natremia
HCTZ Elimination
Excreted 50-70% unchanged in urine
HCTZ Clinical Pearls
Full hypotensive effect may require 2-3 weeks
Avoid Alcohol and other NSAIDs
Ibuprofen Classification/Indication
NSAID
Pain relief, fever, HA
Ibuprofen Dosing
200-400mg po q4-6h prn
Ibuprofen MOA
Nonselective COX inhibiter. Reversibly alters platelet functioning and prolongs bleeding time
Ibuprofen ADE
GI Distress/Bleeding
Edema, Itching
Ibuprofen Clinical Pearls
Use with caution in renal dysfunction.
NSAIDs associated w/increased risk of CV thrombotic events
Levofloxacin (Levoquin) Classification/Indication
Antibiotic
Treatment of community-acquired pnemonia, including multidrug resistance strains of S. PNEMONIAE (MDRSP) nosocomial pnemonia, chronic bronchitus (acute bacterial exacerbaction) acute bacterial rhinosinusitis (ARBS) prostatitis (chronic bacterial) UTI (complication or un) acute pyelonephritis, skin infections, reduces incidence or disease progression of inhalational anthrax (post exposure)
Ibuprofen Elimination
Hepatic metabolism via. CYP2C19
45-80% renal elim?
Levofloxacin Dosing
500-750mg 1D
Levofloxacin MOA
The S- enantomer of the floroquinolone, ofloxacin, levofloxacin inhibits DNA-gyrase in susceptible organisms thereby inhibits relaxation of supercoiled DNA and promotes breakage of DNA strands. DNA topoisomerase (tygrase)II is an essential bacterial enzyme that maintains the superhelical structure of DNA and is required for DNA replication transcription, repair, recombination and transposition.
Levofloxacin ADE
Nausea
HA
Diarrhea
Levofloxacin Elimination
CrCl 20-50 reduce dose by 50% (RENALLY EMINIATED)
CrCL 5-19 ml/min extend interval by 48H
Levofloxacin Clinical Pearls
Not approved in children younger than 18 y/o. Oral and IV dosing is interchangeable. Increased risk of tendon rupter in >60y/o.
Losartan Classification/Indication
Antihypertension
Hypertension, diabetic nephropathy
Losartan Dosing
50mg 1D
Losartan MOA
Selective and competative Nonpeptide ATII receptor antagonist, blocks vasoconstrictor and aldosterone-secreting effects of ATII.
Interacts reversibly at AT1 and AT2 receports of many tissues and has slow dissociation kinetics. Affinity for AT1r is 1000x grater than AT2r. Angiotension II receptor antagonists may induce a complete inhibition of renin-antagonists may induce more complete inhibition of RAAS system than ACE inhibitors, they do not affect the response to bradykinin, and are less likely to be associated with nonrenin-angiotensin effects.
Losartan increases urinary flow rate and in addition to being natriuretic and kaliuretic increases excretion of chloride, magnesium, UA, calcium and phosphate.
Losartan ADE
HA
Diarrhea
Hyperkalemia
Losartan Elimination
GFR <30 ml/min/1.73m2: use not recommended!
Hepatic mild to moderate impairment: 25mg 1D
Losartan Clinical Pearls
ACEi induced cough
Metformin (Glucophage) Classification/Indication
Antidiabetic
DMII
Metformin Dosing
500mg BID or 850mg 1D; Titrate in increments of 500mg weekly or 850mg QOW
Metformin MOA
Decreases hepatic glucose production, decreasing intestinal absorption of glucose and improves insulin sensitivity (increases peripheral glucose uptake and utilization)
Metformin ADE
Diarrhea
N&V
Flatulence
Metformin Elimination
Renal elimination
contraindicated in eGFR <30
eGFR 30 to 45 may consider 50% dosage reduction
Metformin Clinical Pearls
Does not cause hypoglycemia, need good renal function measured by GFR, not SCr anymore
Simvastatin (Zocor) Classification/Indication
Hypolipemic
Hyperlipidemia; prophylaxis for CVD event risk
Simvastatin Dosing
5-40mg PO D (dependent on intensity)
Simvastatin MOA
Hydrolyzed to beta-hydroxyacid (potent HMG-CoA reductase inhibitor) increases rate of removal of cholesterol from body and reduces production by inhibiting conversion of HMG-CoA to mevolanate (early and rate limiting step in biosynthesis of cholesterol)
Simvastatin ADE
Myalgia, rhabdomyolysis
Abdominal pain
Increased LFTs
Simvastatin Elimination
Extensive hepatic metabolism
Renal and fecal elimination
Simvastatin Clinical Pearls
Avoid during pregnancy
SX’s muscle pain/weakness
Take in evening
CYP3A4 DDinx limit to 20mg w/ amiodarone, amlodipine, ranolazine. Limit to 10 mg w/ verapamil, diltiazem, dronedarone.
Do not initiate 80mg- restricted to pts who received that dose chronically for at least 12 months w/o evidence of muscle tox.
Metoprolol Succinate (Toprol XL) Metoprolol Tartrate (Lopressor) Classification/Indication
Betablocker (antihypertensive)
Angina, heart failure, HTN, MI
Succinate/Tartrate Dosing
25 mg po D
Succinate/Tartrate MOA
Selective inhibitor of beta1 adrenergic receptors; competatively blocks b-1 with little to no effect on b2 receptors at oral doses <100mg. Does not exhibit any membrane stabilizing or intrinsic sympathomimetic activity
Succinate/Tartrate ADE
Dizziness, Fatigue, Hypotension
Succinate/Tartrate Elimination
Liver disease- use slow dose titration
Succinate/Tartrate Clinical Pearls
Avoid concomitant use of CCBs as use may significantly affect heart rate rhythms.